Coherus BioSciences, Inc. (CHRS)

NASDAQ: CHRS · IEX Real-Time Price · USD
8.49
+0.01 (0.12%)
Feb 1, 2023, 10:31 AM EST - Market open
0.12%
Market Cap 659.56M
Revenue (ttm) 239.06M
Net Income (ttm) -278.61M
Shares Out 77.78M
EPS (ttm) -3.59
PE Ratio n/a
Forward PE 32.89
Dividend n/a
Ex-Dividend Date n/a
Volume 83,775
Open 8.45
Previous Close 8.48
Day's Range 8.34 - 8.55
52-Week Range 5.58 - 14.11
Beta 0.87
Analysts Buy
Price Target 18.11 (+113.31%)
Earnings Date Feb 16, 2023

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab bios... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2014
Employees 376
Stock Exchange NASDAQ
Ticker Symbol CHRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $18.11, which is an increase of 113.31% from the latest price.

Price Target
$18.11
(113.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential

3 weeks ago - GlobeNewsWire

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan...

1 month ago - GlobeNewsWire

Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc...

3 months ago - Zacks Investment Research

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

– UDENYCA® net sales of $45.4 million in the third quarter 2022 – – CIMERLI™ launched in the United States on October 3 rd – – Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ a...

3 months ago - GlobeNewsWire

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market...

3 months ago - GlobeNewsWire

Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022

- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis ®  (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity -

4 months ago - GlobeNewsWire

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual...

5 months ago - GlobeNewsWire

Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing

Coherus BioSciences (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...

5 months ago - Zacks Investment Research

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation committee...

5 months ago - GlobeNewsWire

Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Coherus BioSciences (CHRS). While the effectiveness of this highly sought-after metric is questionable...

5 months ago - Zacks Investment Research

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

– Commercial launch of CIMERLI™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planned July 2023 launch of YUSIMRY™ – – ...

6 months ago - GlobeNewsWire

Wall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know

The consensus price target hints at an 84.6% upside potential for Coherus BioSciences (CHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

6 months ago - Zacks Investment Research

FDA Approves Coherus' CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

- CIMERLI™ is Coherus' third FDA-approved product and the first of four new product launches planned by the end of 2023 -

6 months ago - GlobeNewsWire

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after marke...

6 months ago - GlobeNewsWire

Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

- Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies -

9 months ago - GlobeNewsWire

Coherus BioSciences Management to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in...

9 months ago - GlobeNewsWire

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Coherus BioSciences Reports First Quarter 2022 Results

– CIMERLI ™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1 st quarter 2022 net sales of $60.1 million – – 2022 R&...

9 months ago - GlobeNewsWire

Coherus BioSciences Appoints Charlie Newton to Board of Directors

- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus' immuno-oncology strategy execution -

9 months ago - GlobeNewsWire

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngea...

9 months ago - Benzinga

CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Infor...

9 months ago - GlobeNewsWire

Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the c...

9 months ago - GlobeNewsWire

Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

7 Biotech Stocks to Buy With Key Catalysts for April

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel...

Other symbols: ALNYAPTXBMYBPMCHCMTARS
10 months ago - InvestorPlace